<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00006044</url>
  </required_header>
  <id_info>
    <org_study_id>99-115</org_study_id>
    <secondary_id>P30CA008748</secondary_id>
    <secondary_id>P01CA005826</secondary_id>
    <secondary_id>MSKCC-99115</secondary_id>
    <secondary_id>NCI-G00-1818</secondary_id>
    <nct_id>NCT00006044</nct_id>
  </id_info>
  <brief_title>Testosterone in Treating Patients With Progressive Prostate Cancer That No Longer Responds to Hormone Therapy</brief_title>
  <official_title>A Phase I Trial of Testosterone in Patients With Progressive Androgen-Independent Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: High doses of testosterone may be effective in killing prostate cancer cells that&#xD;
      no longer respond to hormone therapy.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of testosterone in treating patients who&#xD;
      have progressive prostate cancer that no longer responds to hormone therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the safety and maximum tolerated dose of exogenously administered testosterone&#xD;
           in patients with progressive androgen-independent prostate cancer who have been in&#xD;
           castrate state either surgically or pharmacologically for a minimum of 1 year.&#xD;
&#xD;
        -  Assess the changes in expression of androgen receptor and other receptors in human&#xD;
           biopsy specimens or circulating tumor cells before and after this treatment in this&#xD;
           patient population.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study.&#xD;
&#xD;
      Patients receive testosterone via an enhanced absorption transdermal system continuously for&#xD;
      28 days. The transdermal patches are changed daily.&#xD;
&#xD;
      Cohorts of 3-6 patients receive a fixed daily dose of testosterone with escalating duration&#xD;
      of exposure until the maximum tolerated dose (MTD) is determined. The MTD is defined as the&#xD;
      dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicities.&#xD;
&#xD;
      Patients are followed at day 1 and at weeks 2 and 4.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 3-18 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2000</start_date>
  <primary_completion_date type="Actual">February 2005</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Prostate Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>therapeutic testosterone</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed androgen independent metastatic prostate cancer&#xD;
&#xD;
          -  Progressive disease manifested by either:&#xD;
&#xD;
               -  New osseous lesions by bone scan or a greater than 25% increase in&#xD;
                  bidimensionally measurable soft tissue disease or the appearance of new sites of&#xD;
                  disease by MRI or CT scan OR&#xD;
&#xD;
               -  Minimum of 3 rising PSA values from baseline that are obtained 1 week or more&#xD;
                  apart, or 2 rising PSA values more than 1 month apart, where the percentage&#xD;
                  increase over the range of values is at least 25%&#xD;
&#xD;
          -  Castrate state by orchiectomy or gonadotropin-releasing hormone analogues for minimum&#xD;
             of 1 year&#xD;
&#xD;
               -  Testosterone no greater than 30 ng/mL&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
          -  Metastatic disease by bone scan, MRI, or CT scan&#xD;
&#xD;
          -  Rising PSA values&#xD;
&#xD;
          -  If receiving antiandrogen therapy, must have shown progressive disease off treatment&#xD;
&#xD;
          -  No active CNS or epidural tumor&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Karnofsky 60-100%&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC at least 3,500/mm^3&#xD;
&#xD;
          -  Platelet count greater than 100,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin less than 2.0 mg/dL&#xD;
&#xD;
          -  SGOT less than 3 times upper limit of normal&#xD;
&#xD;
          -  PTT less than 14 seconds&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine less than 2.0 mg/dL OR&#xD;
&#xD;
          -  Creatinine clearance greater than 60 mL/min&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No New York Heart Association class III or IV cardiac disease&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  No severe debilitating pulmonary disease&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No infection requiring IV antibiotics&#xD;
&#xD;
          -  No other severe medical problems that would increase risk for toxicity&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Recovered from prior biologic therapy&#xD;
&#xD;
          -  No concurrent immunotherapy&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  Recovered from prior chemotherapy&#xD;
&#xD;
          -  No concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  If no prior orchiectomy, must continue on gonadotropin-releasing hormone analogs to&#xD;
             maintain castrate levels of testosterone&#xD;
&#xD;
          -  No concurrent finasteride&#xD;
&#xD;
          -  No other concurrent hormonal therapy&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  Recovered from prior radiotherapy&#xD;
&#xD;
          -  No concurrent radiotherapy to an indicator lesion&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Recovered from prior surgery&#xD;
&#xD;
          -  No concurrent surgery on only measurable lesion&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  At least 4 weeks since other prior investigational anticancer drugs and recovered&#xD;
&#xD;
          -  No other concurrent investigational anticancer agents&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Morris, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Morris MJ, Huang D, Kelly WK, Slovin SF, Stephenson RD, Eicher C, Delacruz A, Curley T, Schwartz LH, Scher HI. Phase 1 trial of high-dose exogenous testosterone in patients with castration-resistant metastatic prostate cancer. Eur Urol. 2009 Aug;56(2):237-44. doi: 10.1016/j.eururo.2009.03.073. Epub 2009 Apr 3.</citation>
    <PMID>19375217</PMID>
  </results_reference>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>July 5, 2000</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>January 17, 2013</last_update_submitted>
  <last_update_submitted_qc>January 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 18, 2013</last_update_posted>
  <keyword>stage IV prostate cancer</keyword>
  <keyword>recurrent prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Testosterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

